(SEM) number of gastric and duodenal bacterial counts was 6.0 (0.2) and 5.0 (0.2) respectively in the omeprazole group and 4.0 (0.2) and 4.0 (0.1) in the cimetidine group (p<0,001 and <0'01; respectively).
Faecal type bacteria were found in 30% of the patients with bacterial overgrowth. Basal gastric pH was higher in patients treated with omeprazole compared with cimetidine (4.2 (0.5) versus 2-0 (0.2); p<0.001) and in patients with bacterial overgrowth compared with those without bacterial overgrowth (5.1 (0.6) versus 2.0 (0.1); p<0.0001). The nitrate, nitrite, and nitrosamine values in gastric juice did not increase after treatment with either cimetidine or omeprazole. Serum concentrations of vitamin B12, P carotene, and albumin were similar before and after treatment with both drugs.
Conclusions-These results show that the incidence of gastric and duodenal bacterial overgrowth is considerably higher in patients treated with omeprazole compared with cimetidine. This can be explained by more pronounced inhibition of gastric acid secretion. No patient developed signs of malabsorption or an increase of N-nitroso compounds. The clinical significance of these findings needs to be assessed in studies with longterm treatment with omeprazole, in particular in patients belonging to high risk groups such as HIV infected and intensive care units patients. (Gut 1996; 39: 54-59) Keywords: bacterial overgrowth, omeprazole, cimetidine, nitrates, nitrites, N-nitroso compounds.
The major control factor for bacterial survival in the stomach is the acidity of gastric contents. Gastric and duodenal bacterial overgrowth frequently occurs The aim of this prospective, randomised, double blind study was therefore to evaluate the incidence of gastric and duodenal bacterial overgrowth in patients with peptic ulcer disease treated with omeprazole compared with patients treated with cimetidine and to investigate the relations between the degree of bacterial colonisation and gastric values of N-nitroso compounds.
Methods

Patients
The study was performed in 47 outpatients (mean age 42; range 20 to 69; eight women) referred for routine diagnostic endoscopy. These patients had not taken antisecretory drugs or antibiotics during the month prior to the first endoscopy. Patients with diabetes or immunity disorders and those with low gastric acidity at the first endoscopy (intragastric pH>4) were excluded. Endoscopy at inclusion showed the presence of reflux oesophagitis in 28 patients, duodenal ulcer in eight, gastric ulcer in five, and gastric or duodenal erosions, or both, in six patients.
Each patient received in a double blind, random order 20 mg omeprazole with breakfast and placebo with dinner during four weeks or 800 mg cimetidine with dinner and placebo with breakfast during four weeks. All patients were investigated one day before and one day after the treatment course. Thus, the last omeprazole capsules were taken 24 hours and the last cimetidine dose 12 hours before endoscopy.
Ten of 47 patients were excluded during the study: gastric biopsies showed an adenocarcinoma in one patient, compliance was bad in five patients, one was lost for control purposes, and treatment was stopped in three patients presenting with diarrhoea (two with omeprazole, one with cimetidine). In these three patients, diarrhoea disappeared within two days upon cessation of treatment, suggesting a side effect of the drug itself rather than an effect of bacterial overgrowth (patients did not undergo control endoscopy).
All endoscopic examinations were performed for clinical indications and written informed consent was obtained before participation. The study was approved by the medical ethical committee of the University Hospital of Lausanne.
Sampling procedure An Olympus GIF-Q20 endoscope was used for all investigations. A double sheathed plastic wash pipe (Mauch, Munchenstein, Switzerland) was used to collect the aspirates under sterile conditions. The pipe was constructed by passing one Teflon coated plastic tube (diameter 1 mm) inside another (diameter 2.3 mm). The end of the outer tube was covered by a thin rubber plug vulcanised into its tip, so that the interior of the outer tube containing the inner tube remained sterile until the rubber plug was pierced by pushing the inner tube out of the outer tube. After assembling both tubes and vulcanisation of the rubber plug into the tip of the outer tube, the whole assembly was sterilised by autoclaving for 20 minutes at
1200C.18
All endoscopy procedures were performed after an overnight fast. No local anaesthesia was used. The patients were sedated with 2.5 to 5 mg midazolam given intravenously. Fluid samples were obtained under endoscopic visualisation in the stomach (10 ml) and about 20 cm beyond the pylorus (1 ml). Every effort was made to avoid contamination of gastric juice with saliva. Aspirates were collected in a sterile syringe and 1 ml immediately transferred to an anaerobic transport vial (Port-AGerm, BioMerieux, France). The pH value and concentrations of nitrate, nitrite, and nitrosamine compounds were also measured in gastric samples (IARC, Lyon, France). Serum samples were taken in all patients at first and second endoscopy for vitamin B 12, betacarotene, and albumin measurements.
Bacteriological culture
The microbiologists who cultured the duodenal and gastric aspirates had no knowledge of the clinical or endoscopic findings; nor were they informed about the treatment regimen of the patients. The contents of the transport vial were measured (volume) and quantitatively plated for both aerobic and anaerobic organisms. The samples were Patients (n) who had bacterial overgrowth. a Haemolytic or non-haemolytic streptococci, or both, were 104cfu/ml) in stomach and duodenum ofpatients with found in all patients. Gram negative Enterobacteriaceae were identified in three patients (klebsiella species in one patient, Escherischia coli in the two groups were compared by the non-in two patients), and pseudomonas species in parametric Mann-Whitney U test. Difference one patient. Anaerobes were recovered from was considered significant with p values two patients (bacteroides species) and entero-<0 05.
cocci from one patient. In four of 13 patients with bacterial overgrowth (30%), faecal type bacteria (Escherischia coli, bacteroides species, Results enterococci, and klebsiella species) were found Before treatment with omeprazole or cimeti-whereas only oral and pharyngeal type bacteria dine three patients (8%) had bacterial over-were identified in the other patients. There was growth: in one patient staphylococci were no difference in the distribution of bacterial found in gastric and duodenal aspirates (3 105 types in patients treated with omeprazole or cfu/ml); in two patients at haemolytic strepto-cimetidine. cocci, non-haemolytic streptococci, staphyloIn six of seven patients with combined cocci or corynebacterium species were gastric and duodenal bacterial overgrowth, all detected in duodenal samples ( 1 05 cffu/ml) the bacteria cultured in duodenal juice were with sterile gastric aspirates. At the end of the also present in gastric juice. treatment course, gastric or duodenal bacterial Basal gastric pH was higher in patients overgrowth, or both, was present in 10 of 19 treated with omeprazole compared with patients receiving omeprazole (53%) and in cimetidine overgrowth during treatment with H2 antagonists seems to be much lower compared with gastric overgrowth, but there are only a few investigations37 38 and the H2 breath test used as the method of assessment in these studies has a low sensitivity and specificity for duodenal bacterial overgrowth.9 42 Data are far more limited with omeprazole but salmonella gastroenteritis has also been reported in a patient treated with 20 mg omeprazole.'5 Data are also lacking in patients in high risk groups but recently the occurrence of nosocomial infections in intensive care units has been found to be increased by antisecretory treatment with H2 antagonists.24 35 In HIV infected patients, hypochlorhydria, disturbance of gastric emptying, and impaired local immunity have been reported,43-7 and gastric or duodenal bacterial overgrowth was present in 30% of them. 48 Anaerobic colonisation can be associated with malabsorption syndromes leading to steatorrhea and vitamin B 12 deficiency. 12 49 50 Omeprazole has been shown to decrease cobalamine absorption50 and the consequences of longterm treatment with omeprazole are not known. In this study we found no modification of vitamin B 12, P carotene, and albumin blood concentrations in patients with bacterial overgrowth. Our results correspond with those of a recently published study, where no evidence of fat or carbohydrate malabsorption was found in elderly patients with bacterial overgrowth caused by atrophic gastritis or omeprazole treatment. 9 We only treated our patients for four weeks, however, which is probably too short for the development of a pronounced vitamin B 12 deficiency. Further studies with longterm omeprazole treatment are necessary to clarify this issue.
Reduced gastric acid secretion may cause colonisation of nitrate reducing bacteria in the stomach. This has been claimed to increase the formation of potentially carcinogenic Nnitroso compounds.'7 Whether these changes have any clinical significance, and particularly in relation to the development of gastric cancer, has been extensively investigated and debated but remains controversial.51-55 In some studies higher N-nitroso compounds concentrations were found in subjects treated with H2 antagonists6 56 and omeprazole8 while others,364' including our group57 could not confirm these earlier reports. In this study we did not find any significant modification of the gastric nitrate, nitrite, and N-nitroso compounds concentrations during treatment with either cimetidine or omeprazole. One explanation for these controversial results is that the production of bacterially catalysed N-nitroso compounds in the stomach is dependent on the species and strains present58 59 and on the duration of the antisecretory treatment. Indeed, we found only a few nitrate reducing bacteria such as Escherichia coli, pseudomonas, and klebsiella species in the stomach of patients treated with either drug.
To summarise, we found that the incidence of gastric and duodenal bacterial overgrowth was considerably higher in patients treated with 20 mg omeprazole compared with 800 mg cimetidine daily for four weeks, doses usually used and recommended in clinical practice for the treatment of peptic diseases. This result may be explained by the more potent inhibition of gastric acid secretion by omeprazole. The bacterial flora consisted mainly of oral type bacteria. Despite the presence of faecal type bacteria in 30% of the patients, no patient developed a malabsorption syndrome or an increase of N-nitroso compounds. The clinical significance of these findings needs to be assessed in studies with longterm treatment with omeprazole, in particular in patients in high risk groups.
